^
Association details:
| Biomarker: | MALT1 expression |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients
Excerpt:
One patient with metastatic CCA experienced a partial radiographic response to regorafenib that lasted for 5 months...Another CCA patient showed a stable disease for 3.8 months, as well as tumor necrosis after regorafenib treatment...Interestingly, the tumor tissues of both cases were MALT1-positive.
DOI:
10.18632/oncotarget.23049
